J&J's TAR-200 Phase 2b SunRISe-1 Study Shows 84% Complete Response In High-Risk ...

Johnson & Johnson announced Phase 2b SunRISe-1 study results showing TAR-200's 83.5% complete response rate in BCG-unresponsive HR-NMIBC patients, with 82% maintaining response after 9 months.